Cytek Biosciences (CTKB) Change in Accured Expenses (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Change in Accured Expenses data on file, last reported at -$3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 83.4% year-over-year to -$3.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (up 32.51% YoY), and the FY2025 full-year result was $4.0 million, up 585.92% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$3.9 million, down from $4.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.6 million in Q3 2024 and bottomed at -$4.8 million in Q2 2024.
• The 5-year median for Change in Accured Expenses is $335000.0 (2023), against an average of $438941.2.
• Peak annual rise in Change in Accured Expenses reached 2368.91% in 2024, while the deepest fall reached 360.86% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $4.6 million in 2022, then plunged by 97.44% to $119000.0 in 2023, then surged by 2368.91% to $2.9 million in 2024, then soared by 60.28% to $4.7 million in 2025, then slumped by 182.61% to -$3.9 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.9 million (Q1 2026), $4.7 million (Q4 2025), and -$1.4 million (Q3 2025), per Business Quant data.

Peer Comparison